Evidence map›Paper›PMID 38340153›Full record

ArticleAmerican journal of clinical dermatology2024

Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.

Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard B Warren, Andreas Wollenberg, Emma Guttman-Yassky

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Michael CroftCenter for Autoimmunity and Inflammation, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA, 92037, USA. mick@lji.org.ORCID http://orcid.org/0000-0002-6062-3635
Ehsanollah EsfandiariKyowa Kirin International, London, UK.
Camilla ChongKyowa Kirin International, London, UK.
Hailing HsuAmgen Inc., Thousand Oaks, CA, USA.
Kenji KabashimaDepartment of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-0773-0554
Greg KricorianAmgen Inc., Thousand Oaks, CA, USA.ORCID http://orcid.org/0000-0002-9419-9836
Richard B WarrenDermatology Centre, Northern Care Alliance NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.ORCID http://orcid.org/0000-0002-2918-6481
Andreas WollenbergDepartment of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany.ORCID http://orcid.org/0000-0003-0177-8722
Emma Guttman-YasskyDepartment of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Box 1047, New York, NY, 10029-6574, USA. emma.guttman@mountsinai.org.ORCID http://orcid.org/0000-0002-9363-324X
Amgen (United States) · USKyowa Kirin International (United Kingdom) · GBKyoto University · JPLa Jolla Institute for Immunology · USManchester Academic Health Science Centre · GBRockefeller University · USUniversity Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38340153
PMCPMC11070392
OpenAlexW4391716627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.